Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
<p>Abstract</p> <p>Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years, TLS has been more widely observed...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-12-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://www.jhoonline.org/content/5/1/75 |